Biome Australia Nears International Breakeven with FY26 Revenue Growth of 26% Across Four Key Markets

Biome’s Leading Australian Pharmacy Products Form Foundation for International Expansion

Biome Australia has established a dominant position in Australia's complementary medicine market with two flagship products leading their pharmacy categories. Biome Daily Probiotic is Australia's top-selling probiotic in pharmacy scan sales, while Biome Daily Kids Probiotic is the leading kids and immune health probiotic in Australian pharmacies. This success stems from a unique operating model featuring practitioner-only distribution, clinically-supported formulations, and a strict non-discounted pricing strategy, contrasting with competitors who rely on online and discount channels.

The Australian growth story highlights the scalability of Biome’s go-to-market approach, expanding from about 100 to approximately 7,500 points of sale between FY20 and FY26, reflecting a 106 percent compound annual growth rate in distribution coverage. In FY26, same-store sales in Australian accounts increased by 38.6 percent, with roughly 1,600 new accounts added. This proven model now drives international market entry, applying the same practitioner-led, premium positioning across Canada, the UK, Ireland, and New Zealand. The recent update indicates international markets are in the early, rapid growth phase, positioning each to replicate Australia’s distribution expansion from inception.

International Revenue Growth to A$1.8 Million Validates Business Model Across Four Markets

In FY26, Biome’s international operations confirmed the viability of its business model, with revenue rising 26 percent to A$1.8 million from the previous year. This growth occurred across Canada, the United Kingdom, Ireland, and New Zealand, each utilizing optimized channel mixes tailored to local regulatory and retail environments. The international division employs 12 full-time staff across these markets, supports around 2,000 distribution points, and demonstrates independent demand validation in each jurisdiction. While FY25 absolute revenue was undisclosed, the 26 percent year-on-year increase signals strong momentum as market entry and early scaling progress.

The international segment’s profitability trajectory is a key investor consideration. With a gross margin near 68 percent—seven points above domestic margins—the direct-to-practitioner, non-discounted model replicates Australia’s premium unit economics. Notably, international revenue of A$1.8 million nearly matches A$1.82 million in operating expenses, marking near-breakeven status during the build and early scaling phase. This suggests significant operating leverage potential as distribution matures without proportional cost increases.

Group Gross Profit Hits A$1.21 Million at 68% Margin as Operating Leverage Emerges

Biome’s consolidated FY26 financials reveal operating leverage emerging as the company shifts from building to scaling on existing infrastructure. Group gross profit reached A$1.21 million at a blended 68 percent margin across domestic and international operations, reflecting robust unit economics in both Australian retail pharmacy and international practitioner-led channels. Group revenue growth of A$1.8 million outpaced costs, with operating expenses held at A$1.82 million, narrowing the net loss to A$649,000. This margin improvement and loss reduction indicate the company is moving beyond heavy infrastructure investment and poised to benefit from revenue growth on stable operating costs.

Management’s FY27 priorities are set across all four international markets based on infrastructure established in FY26, anticipating margin expansion and contribution leverage as revenue and distribution scale without equivalent cost increases. Presentation materials imply a "contribution flip" beyond FY27, where revenue growth on stable headcount drives breakeven and eventual profitability. This operating leverage is critical for investors assessing the path to cash generation, signaling the capital-intensive build phase is largely complete, with future value driven by revenue execution.

Canada Becomes Largest International Market with Five Distribution Partners

Canada has emerged as Biome’s largest international revenue source, operating in a US$2.5 billion probiotics market in 2023 with a projected 13 percent compound annual growth rate through 2030, per Grand View Research. The Canadian strategy involves partnerships with five distributors covering practitioner and retail channels: Fullscript and Ecotrend serve over 125,000 natural health practitioners; Pure Pharmacy targets integrative pharmacy retail; Health Food Network covers health-food retail; and direct clinic supply completes the channel structure. All partnerships were secured or expanded in FY26, reflecting rapid progress despite early market establishment.

Biome’s competitive edge in Canada is based on practitioner-only distribution, clinically-backed formulations, and strict non-discounting, differentiating it from competitors like Genestra and Metagenics. Expansion priorities include entering Quebec, transitioning FY26 retail banner wins online, increasing Health Canada approvals from 12 to 24 SKUs, and enhancing practitioner education. The Canadian market offers substantial scale relative to Australia and the ability to replicate Biome’s premium, practitioner-only model. Proprietary assets such as the BMB18 strain and Australian manufacturing provide key advantages over legacy and discount-reliant competitors.

Ireland Distribution Expands from 18 to 40 Stores via Uniphar Partnership

In Ireland, Biome is scaling distribution through a partnership with Uniphar, growing retail coverage from 18 to 40 stores. This near doubling demonstrates early scalability of the practitioner-led model in a smaller market, validating demand for clinically-backed, condition-specific probiotics despite lower population density and pharmacy penetration compared to Canada or the UK. The Uniphar partnership grants access to established wholesale and retail relationships, minimizing capital intensity and enabling focus on practitioner education and product positioning.

Ireland’s success confirms Biome’s model works across diverse regulatory and retail environments. As a European market with distinct pharmacy regulations and practitioner licensing, Ireland’s growth shows that the non-discounted, practitioner-led approach meets genuine demand internationally. Doubling distribution coverage provides a near-term milestone for investors tracking international execution.

United Kingdom Market Growth Through Natural Health Partnership

Biome’s UK market entry and scaling are conducted via a partnership with Natural Health (NH), covering sales, marketing, and distribution. The UK probiotics market benefits from strong complementary medicine adoption and a well-established natural health practitioner network, aligning well with Biome’s practitioner-led, non-discounted positioning. The NH partnership provides access to existing practitioner and retail channels, reducing capital needs and accelerating revenue generation.

This capital-efficient UK model leverages established distribution infrastructure while maintaining product positioning and practitioner engagement. Validated across multiple markets, Biome’s partnership approach enables effective market entry without wholly-owned operations. The UK represents a significant international growth opportunity due to its large complementary medicine sector and practitioner ecosystem aligned with Biome’s strategy.

New Zealand Launch Through ProPharma and Practitioner Channels

New Zealand, Biome’s newest international market, is in launch phase with partnerships via ProPharma and practitioner channels. The market resembles Australia’s structure with strong pharmacy presence and natural health networks, making it a natural geographic extension. The ProPharma partnership, a major pharmacy wholesaler and distributor, combined with direct practitioner relationships, provides immediate retail and practitioner access without capital-intensive development. Although smaller than Canada or the UK, New Zealand offers geographic diversification and a platform to refine the market entry approach.

As the most recent international market, New Zealand serves as a near real-time test of Biome’s ability to secure distribution partners, establish practitioner relationships, and build presence. Success would validate the model’s adaptability across markets, while challenges would offer learning opportunities for future entries or partner strategies.

B Corporation Certification and Proprietary IP Strengthen Competitive Edge

Biome Australia’s B Corporation certification aligns it with global standards for inclusive, equitable, and regenerative business practices. This reflects commitment to social and environmental responsibility, benefiting employees and communities, alongside governance emphasizing accountability and transparency. B Corp status differentiates Biome in the complementary medicine sector, appealing to practitioners and consumers valuing corporate responsibility beyond financial returns, supporting education and brand positioning.

The company’s proprietary intellectual property, including partnerships with leading microbiome researchers and ownership of the BMB18 strain, combined with Australian onshore manufacturing, offers competitive advantages over legacy and emerging probiotic brands. These assets enable ongoing clinical validation and innovative formulations, supporting Biome’s clinically-backed positioning globally. Onshore manufacturing enhances supply chain resilience and quality control, critical as international distribution scales. These factors create barriers to competition and underpin the premium, non-discounted, practitioner-only model across all markets.

FY27 Focus on Scaling Using Established Infrastructure Across All Markets

Management confirmed FY27 priorities are fixed across all four international markets, leveraging infrastructure built during FY26. This indicates confidence that foundational elements—partner relationships, distribution networks, practitioner education, and operational teams—are in place to shift focus toward execution and scaling rather than further infrastructure investment. The staged development approach reduces risk by validating demand and partner performance before aggressive scaling.

This prioritization impacts investor expectations for FY27 revenue and margin growth. With infrastructure set, Biome is positioned to accelerate revenue without proportional cost increases, driving operating leverage and contribution margin improvements. Transitioning from build to scale with stable headcount supports improved cash flow and reduced losses as revenue grows. Investors should monitor FY27 progress in all markets, focusing on distribution expansion, same-store sales, and advancement toward the contribution margin flip anticipated beyond FY27.